1. Market Research
Atopic Dermatitis Therapeutics in Southeast Asia Markets to 2024 - Growth Driven by Rising Awareness and Expected Launch of Novel Therapies

Atopic Dermatitis Therapeutics in Southeast Asia Markets to 2024 - Growth Driven by Rising Awareness and Expected Launch of Novel Therapies

  • November 2018
  • 113 pages
  • ID: 5664242
  • Format: PDF
  • By GlobalData


Table of Contents

Search Inside

Atopic Dermatitis Therapeutics in Southeast Asia Markets to 2024 - Growth Driven by Rising Awareness and Expected Launch of Novel Therapies

Atopic Dermatitis (AD), also called Atopic Eczema, is a chronic, pruritic, inflammatory skin disease associated with cutaneous hyper reactivity to environmental stimulants, with a wide range of severity. Patients typically experience periods of remission that are marked by acute inflammatory relapses known as ‘flares’. It is one of the most common skin diseases, affecting approximately 20% of children and 1-3% of adults in most countries. Atopic Dermatitis (AD) is slightly more common in males aged 6-7 and in females aged 13-14.

Atopic Dermatitis (AD) is a complex disease with a wide spectrum of symptoms affecting 15-20% of children and 1-3% of adults globally. Recent studies showed that its incidence has increased two to three fold in industrialized countries and its prevalence is increasing rapidly in low-income countries. The rising prevalence population, together with improving health awareness among the public and healthcare professionals, special healthcare programs, increasing health-insurance coverage, healthcare access and affordability will increase diagnosis and the treatment-receiving population, driving demand and contributing to market growth.

Southeast Asian Atopic Dermatitis (AD) market (South Korea, Singapore, Taiwan, Malaysia, the Philippines, Thailand, Vietnam, and Indonesia) is forecast to grow at a compound annual growth rate (CAGR) of 10.5% from 2017 to 2024.

The increase in uptake of recently approved and emerging targeted therapeutics, along with the continued uptake of existing branded therapies, will also propel market growth. Dupixent has the potential to be a game-changing therapy, as it is a first-in-class IL-drug and the first biologic approved for the treatment of Atopic Dermatitis (AD). In addition, Dupixent’s expected launch in Singapore and Taiwan will be the most important event in the Atopic Dermatitis (AD) market space in the near-term. The continued uptake of this novel targeted therapy will contribute to the increasing ACoT and in turn drive the market in South Korea, Singapore and Taiwan.

In recent years, targeted therapies have become a focus for Atopic Dermatitis (AD) treatment research. Biologics, small molecule and other therapies targeting specific immune pathways for Atopic Dermatitis (AD) are currently being studied in various phases along the drug development pipeline. The late-stage pipeline contains promising therapies that have the potential to achieve approval and launch over the forecast period.

On the other hand, novel topical therapies are still needed in the Atopic Dermatitis (AD) disease space, as current topical options are limited to corticosteroids and calcineurin inhibitors, which are associated with side effects, a long treatment duration, and low compliance. The launch of new pipeline therapies with better clinical profiles will significantly increase the treatment options for Atopic Dermatitis (AD) patients and improve care levels. Due to the positive impact expected to be made by therapies over the forecast period, the Atopic Dermatitis (AD) market is anticipated to undergo expansion in South East Asia.

- The Southeast Asia AD market will be valued at $848.6m in 2024, growing from $423.2m in2017, at a compound annual growth rate of 10.5%.
- What are the key factors driving the Southeast Asia AD treatment market?
- What classes of drugs dominate the market?
- How will the market respond to recent approval?
- How will novel IL-4Ra inhibitor therapy Dupixent, which holds first-to-market advantage, contribute to growth?
- The AD pipeline contains a range of molecule types and molecular targets, including those that are well established in AD and novel target therapies.
- Which classes of novel drugs are most prominent in the pipeline?
- What are the common targets and mechanisms of action of pipeline therapies?
- Late-stage pipeline therapies with a strong clinical record have the potential to enter the market over the forecast period.
- How have the late-stage therapies performed in clinical trials?
- What are the commercial prospects for the most promising late-stage products?
- How will the approval of tralokinumab, furestem-AD, baricitinib, PAC-14028 and PF-04965842, affect the competitive landscape?
- Various drivers and barriers will influence the market over the forecast period.
- Which factors are most likely to drive the market in these countries?
- What licensing and co-development deals have occurred within this therapy area since 2007?

Reasons to buy
This report will enable you to:
- Understand the current clinical and commercial landscape of AD by considering epidemiology, symptoms, etiology and pathophysiology, diagnosis, prognosis and treatment guidelines and options.
- Visualize the composition of the AD market in terms of the dominant therapies for each patient subset, along with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the market.
- Identify key pipeline trends in terms of molecule type, administration route, molecular target, and novelty.
- Consider market opportunities and potential risks by examining trends in AD clinical trial size, duration, and failure rate by stage of development, molecule type, and molecular target.
- Understand the potential of late-stage therapies with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
- Predict AD market growth in the eight assessed Southeast Asian markets, with epidemiological and annual cost of therapy forecasts across South Korea, Singapore, Taiwan, Malaysia, the Philippines, Thailand, Vietnam, and Indonesia, as well as the individual contributions of promising late-stage molecules to market growth.
- Discover trends in licensing and co-development deals concerning AD products and identify the major strategic consolidations that have shaped the commercial landscape.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
25% Off


  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.


Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on